Arexvy is recommended for adults aged 50-59 when the risk of severe respiratory syncytial virus (RSV) disease increases by the US Advisory Committee on US Vaccination Practices

Arexvy is recommended for adults aged 50-59 when the risk of severe respiratory syncytial virus (RSV) disease increases by the US Advisory Committee on US Vaccination Practices